Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Meets Estimates

Danaher (NYSE:DHR) posted its earnings results on Wednesday. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14, RTT News reports. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter in the previous year, the business posted $2.09 earnings per share.

Danaher Stock Down 10.0 %

DHR opened at $223.12 on Thursday. Danaher has a fifty-two week low of $223.00 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a fifty day moving average of $236.09 and a 200-day moving average of $253.66. The company has a market capitalization of $161.16 billion, a P/E ratio of 42.58, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.48%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analyst Ratings Changes

A number of equities research analysts recently commented on DHR shares. Royal Bank of Canada dropped their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a report on Friday, December 13th. Wells Fargo & Company dropped their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday. Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Finally, KeyCorp lifted their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $280.57.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.